{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:03Z","timestamp":1786715103315,"version":"build-2736575974"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0301-4738.178154","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T02:05:18Z","timestamp":1457316318000},"page":"4","source":"Crossref","is-referenced-by-count":23,"title":["Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?"],"prefix":"10.4103","volume":"64","author":[{"given":"Arup","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PaulG","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finny","family":"Monickaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.178154-1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09286580701396720","article-title":"Overview of epidemiologic studies of diabetic retinopathy","author":"Klein","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.4103\/0301-4738.178154-2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"key-10.4103\/0301-4738.178154-3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra021678","article-title":"Diabetic retinopathy","author":"Frank","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0301-4738.178154-4","doi-asserted-by":"crossref","unstructured":"Kuwabara T, Cogan DG. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963;69:492-502.","DOI":"10.1001\/archopht.1963.00960040498013"},{"key":"key-10.4103\/0301-4738.178154-5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-4835(88)80025-3","article-title":"ATP causes retinal pericytes to contract in vitro","author":"Das","year":"1988","journal-title":"Exp Eye Res"},{"key":"key-10.4103\/0301-4738.178154-6","doi-asserted-by":"crossref","unstructured":"Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, editor. Retina. Vol. II. Philadelphia: Elsevier Mosby; 2006. p. 1241-70.","DOI":"10.1016\/B978-0-323-02598-0.50072-0"},{"key":"key-10.4103\/0301-4738.178154-7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: A unifying mechanism","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"key-10.4103\/0301-4738.178154-8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00281-008-0111-x","article-title":"Immunological mechanisms in the pathogenesis of diabetic retinopathy","author":"Adamis","year":"2008","journal-title":"Semin Immunopathol"},{"key":"key-10.4103\/0301-4738.178154-9","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","article-title":"Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition","author":"Miyamoto","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0301-4738.178154-10","doi-asserted-by":"crossref","first-page":"e108508","DOI":"10.1371\/journal.pone.0108508","article-title":"Chemokine mediated monocyte trafficking into the retina: Role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy","author":"Rangasamy","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/0301-4738.178154-11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of vitreous inflammatory factors with diabetic macular edema","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-12","unstructured":"Labriola LT, Kesen M, Csaky KG. Pharmacokinetics of anti-vascular endothelium growth factor pharmacological agents. In: Das A, Friberg TR, editors. Therapy for Ocular Angiogenesis. Philadelphia: Wolters Kluwer Lippincott Williams Wilkins; 2011. p. 140-53."},{"key":"key-10.4103\/0301-4738.178154-13","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","author":"Heiduschka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.178154-14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","article-title":"Aflibercept (VEGF-TRAP): The next anti-VEGF drug","author":"Stewart","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"key-10.4103\/0301-4738.178154-15","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-16","doi-asserted-by":"crossref","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.","DOI":"10.1016\/j.ophtha.2006.05.064"},{"key":"key-10.4103\/0301-4738.178154-17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/jop.2013.0049","article-title":"Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye","author":"Bakbak","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.4103\/0301-4738.178154-18","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-19","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","author":"Kurihara","year":"2012","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0301-4738.178154-20","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.e1.","DOI":"10.1016\/j.ophtha.2009.04.023"},{"key":"key-10.4103\/0301-4738.178154-21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/2013.jamaophthalmol.91","article-title":"Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment","author":"Do","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-22","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"key-10.4103\/0301-4738.178154-24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results","author":"Elman","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","article-title":"Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-26","first-page":"972","article-title":"A2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3","author":"Rajendram","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-27","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-29","first-page":"1193","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","author":"Diabetic","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0301-4738.178154-30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"et al.Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-31","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0301-4738.178154-32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.178154-33","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.e35.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"key-10.4103\/0301-4738.178154-34","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35.e2.","DOI":"10.1016\/j.ophtha.2010.12.028"},{"key":"key-10.4103\/0301-4738.178154-35","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":", Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-36","first-page":"2137","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial","author":"Writing","year":"2015","journal-title":"JAMA"},{"key":"key-10.4103\/0301-4738.178154-37","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: Pathophysiology and novel therapeutic targets","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.178154-38","unstructured":"Nguyen Q. High Dose Ranibizumab for Diabetic Macular Edema: Month 24 Outcomes of the READ-3 Study (Ranibizumab for Edema of the mAcula in Diabetes \u2013 Protocol 3). Abstract, American Society of Retina Specialists Meeting; 2014."},{"key":"key-10.4103\/0301-4738.178154-39","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I\/II study. Am J Ophthalmol 2013;155:697-704, 704.e1-2.","DOI":"10.1016\/j.ajo.2012.09.032"},{"key":"key-10.4103\/0301-4738.178154-40","unstructured":"Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration. Available from: . [Last accessed on 2016 Feb 17]."},{"key":"key-10.4103\/0301-4738.178154-41","unstructured":"Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Available from: . [Last accessed on 2016 Feb 17]."},{"key":"key-10.4103\/0301-4738.178154-42","unstructured":"Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema. Available from: . [Last accessed on 2015 Nov 18]."},{"key":"key-10.4103\/0301-4738.178154-43","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1167\/iovs.10-6386","article-title":"A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy","author":"Rangasamy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.178154-44","unstructured":"Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial. Available from: . [Last accessed on 2015 Nov 18]."},{"key":"key-10.4103\/0301-4738.178154-45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2337\/dc09-2372","article-title":"Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study","author":"Sfikakis","year":"2010","journal-title":"Diabetes Care"},{"key":"key-10.4103\/0301-4738.178154-46","unstructured":"Scmidt M, Tisdale A, Lowden P, Kovalchin J, Furfine ES. Optimized IL-6 Blockade for the Treatment of Diabetic Macular Edema. Abstract, Association for Research in Vision and Ophthalmology (ARVO) Meeting; 2014."},{"key":"key-10.4103\/0301-4738.178154-47","unstructured":"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2\/5 Receptor Antagonist With Ranibizumab In Adults WithDiabetic Macular Edema. Available from: . [Last accessed on 2016 Feb 17]."},{"key":"key-10.4103\/0301-4738.178154-48","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.2337\/db15-0317","article-title":"Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema","author":"Kita","year":"2015","journal-title":"Diabetes"},{"key":"key-10.4103\/0301-4738.178154-49","unstructured":"KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema. Available from: . [Last accessed on 2015 Nov 18]."},{"key":"key-10.4103\/0301-4738.178154-50","unstructured":"Allegro Ophthalmics Begins Phase 2 Clinical Trial of Luminate \u00ae (ALG-1001) for the Treatment of Diabetic Macular Edema. Available from: . [Last accessed on 2015 Nov 18]."}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:07Z","timestamp":1786713907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0301-4738.178154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"alternative-id":["178154"],"URL":"https:\/\/doi.org\/10.4103\/0301-4738.178154","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}